# Mark Lee

> Mark Lee, MD, PhD is the CEO and Co-Founder of N-Power Medicine, a Redwood City-based company reinventing how oncology clinical trials reach patients. A medical oncologist and scientist trained at Stanford and Harvard, Lee has spent his career at the frontier of personalized medicine - from developing Oncotype DX diagnostics at Genomic Health, to helping build early cancer detection at GRAIL, to leading personalized healthcare at Genentech/Roche. In 2021, he co-founded N-Power Medicine to embed research infrastructure directly into community oncology clinics, combining AI, embedded staff, and real-time registries to dramatically expand clinical trial access. After raising a $72M Series B led by Merck's Global Health Innovation Fund, N-Power acquired Syapse in late 2024 to build the largest community-based prospective clinical research network in oncology.

- **Role:** CEO & Co-Founder at N-Power Medicine, Inc.
- **Organizations:** N-Power Medicine, Inc., Foresight Diagnostics (Board Member)
- **Nationality:** American
- **Education:** Bachelor of Science, Biological Sciences, Stanford University, PhD, Biological Chemistry and Molecular Pharmacology, Harvard University, MD; Residency in Internal Medicine; Fellowship in Medical Oncology, Stanford University School of Medicine
- **Known for:** Co-founded N-Power Medicine and raised $72M total including a Series B led by Merck's Global Health Innovation Fund, Led development and clinical validation of Oncotype DX Colon and Prostate Cancer Assays at Genomic Health, Founding team member at GRAIL; built one of the largest clinical research programs in genomic medicine for early cancer detection

## Career timeline

- **1987-1991** — Undergraduate studies in Biological Sciences at Stanford University
- **1991-1996** — PhD in Biological Chemistry and Molecular Pharmacology at Harvard University
- **1996-2006** — MD, internal medicine residency, and medical oncology fellowship at Stanford University; postdoctoral work at Howard Hughes Medical Institute
- **2006** — Associate Medical Director at Genentech
- **2007-2014** — Vice President of Oncology Development at Genomic Health; led development and validation of Oncotype DX Colon and Prostate Cancer Assays
- **2014** — Chief Medical Officer at Boreal Genomics
- **2014-2016** — Lead for Oncology Clinical Sciences at Google[x] Life Sciences
- **2016-2017** — Founding team member and Head of Clinical Development and Medical Affairs at GRAIL, Inc.; built one of the largest clinical genomics research programs for early cancer detection
- **2017-2021** — SVP and Global Head for Personalized Healthcare, Product Development at Genentech/Roche
- **2021** — Co-founded N-Power Medicine, Inc. with Christer Svedman; became CEO
- **2024-07** — N-Power Medicine closed Series B funding round ($72M total), led by Merck Global Health Innovation Fund; announced collaboration with Merck for oncology clinical trials
- **2024-12** — N-Power Medicine acquired Syapse Holdings Inc. in a stock-for-stock exchange, adding 1,000+ oncologists and building the largest community-based prospective oncology research network

## Achievements

- Co-founded N-Power Medicine and raised $72M total including a Series B led by Merck's Global Health Innovation Fund
- Led development and clinical validation of Oncotype DX Colon and Prostate Cancer Assays at Genomic Health
- Founding team member at GRAIL; built one of the largest clinical research programs in genomic medicine for early cancer detection
- Spearheaded Genentech/Roche's transformation of drug development and care delivery using data at scale as SVP
- Led N-Power's acquisition of Syapse to create the largest community-based prospective oncology clinical research network
- Established N-Power's ProECA (Prospective External Control Arms) platform as a novel approach to de-risking drug development
- Board member at Foresight Diagnostics, a precision oncology diagnostics company
- Speaker at PMWC Precision Medicine World Conference 2026

## Latest updates

- **2026-01** — Spoke at PMWC Precision Medicine World Conference 2026 on Prospective External Control Arms (ProECA) and the future of clinical trial design
- **2025-01** — N-Power Medicine completed acquisition of Syapse Holdings Inc., adding 1,000+ oncologists and their patient populations to N-Power's prospective clinical research network
- **2024-07** — N-Power Medicine closed Series B funding ($72M total) led by Merck Global Health Innovation Fund; announced multi-trial collaboration with Merck for non-small cell lung cancer and other oncology indications

## Links

- Website: https://npowermedicine.com
- LinkedIn: https://www.linkedin.com/in/mark-lee-07a8418

---

Profile page: https://yespress.io/mark-lee
Published by YesPress — https://yespress.io
Last updated: 2026-05-07